the point is that the trial wasn’t powered to detect anything less than a 43% reduction in mortality. The fact that it passed the first couple of analyses might mean that there was an improvement. Or there might not be.
So all we know is that the difference is somewhere between 0 and 43% (if we accept that the trial would have been stopped due to harm if mortality was increased in the MSC group). Anything more is speculation until (or if) MSB gives us more data.
Novartis deal on the rocks, page-71
-
- There are more pages in this discussion • 177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |